VEEV Looks 5.0% Undervalued on GF Value™
Veeva Systems (VEEV) shares rose 9% after-hours on August 30, 2026, following stronger-than-expected Q2 results and raised full-year guidance. GF Value™ estimates VEEV as 5.0% undervalued at $276.69, with a GF Score™ of 95. Subscription revenues grew 16% to $766.8M. Insiders sold $18.1M in shares, while 8 gurus hold the stock, with 7 adding positions.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise expectations for continued revenue growth, supporting a bullish outlook for the stock.
Market read
Earnings beat and guidance lift provide a fresh catalyst for VEEV, likely driving short‑term price appreciation.
What to watch
Potential headwinds from regulatory changes in biotech data handling could affect long‑term growth.
Background
Veeva Systems is a leading provider of cloud‑based software for life‑sciences companies, with a market cap of ~$45 B.
Ticker impact
Veeva Systems reported fiscal 2027 Q2 results that beat expectations and raised full-year revenue and EPS guidance, causing a 9% after‑hours price jump.
Potential continuation of the rally in intraday trading, with upside to near $300 if momentum holds.
Earnings beat, raised guidance, and a valuation discount provide a clear catalyst for buying pressure.
Market effects
Positive for cloud‑software providers serving life‑sciences, may lift peers in the healthcare technology space.
U.S. market sentiment boosted for tech stocks after earnings season.
Highlights demand for SaaS solutions in pharma globally.
Counterpoint
Insider selling and modest momentum rating suggest caution; the stock may be overbought after the sharp move.
Key entities
- companyVeeva Systems Inc
Cloud‑software provider for life‑sciences.
